½ÃÀ庸°í¼­
»óǰÄÚµå
1722757

¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Anesthesia CO2 Absorbent Market Report by Product (Soda Lime, Medisorb, Dragersorb, Amsorb, Litholyme, and Others), Type (Premium, Traditional), End User (Hospitals, Clinics, and Others), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 8,290¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 1¾ï 3,280¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 5.38%¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. º´¿ø ¹× Ŭ¸®´ÐÀÇ ¼ö¼ú °Ç¼ö Áõ°¡·Î ÀÎÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â Èí¼öÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀåÀÌ È°¼ºÈ­µÇ°í ÀÖ½À´Ï´Ù.

¸¶Ãë¿ë CO2 Èí¼öÁ¦´Â ¸¶Ãë ¼Ò¸ðǰÀÇ Æ¯Á¤ ºÎºÐÀ¸·Î, ÁÖ·Î ¸¶Ãë Åõ¿© Áß È£±â °¡½º¸¦ Èí¼öÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. °­·ÂÇÑ ¼ö»êÈ­Ä®·ý°ú ¼ö»êÈ­³ªÆ®·ý ¿°±â·Î ±¸¼ºµÇ¾î ¸¶Ãë ºÐÀڷκÎÅÍ ÀÏ»êȭź¼Ò(CO)·ÎÀÇ ºÒ¾ÈÁ¤ÇÑ ¾ç¼ºÀÚ È¹µæÀ» µ½´Â ÀÌ Èí¼öÁ¦ Á¦Á¦´Â ¸¶ÃëÁ¦ ³¶ºñ¸¦ ÃÖ¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¸¶Ãë Èí¼öÁ¦·Î ±¸¼ºµÈ CO2 Èí¼ö ÀåÄ¡´Â ¸¶Ãë±âÀÇ È¯±â ÀåÄ¡¿¡ ³»ÀåµÇ¾î ÀÖÀ¸¸ç, ¿øÇü ȸ·ÎÀÇ Èí±â Ãø°ú È£±â Ãø »çÀÌ¿¡ ¼³Ä¡µË´Ï´Ù. ÀÌ ÀåÄ¡´Â ½Å¼±ÇÑ °¡½ºÀÇ È帧À» Æó¼âȸ·Î »óÅ·ΠÁ¦ÇÑÇϰí, È£±âµÈ ¸¶ÃëÁ¦¸¦ ÀçÈ£ÈíÇÏ°Ô ÇÔÀ¸·Î½á ÀÛµ¿ÇÕ´Ï´Ù. ±×·¯³ª ÀÏ»êȭź¼Ò(CO)ÀÇ ¹ß»ýÀº ȯÀÚ¿¡°Ô °Ç°­»óÀÇ À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀϺΠCO2 Èí¼öÁ¦´Â ¼ö»êÈ­Ä®·ýÀ̳ª ¼ö»êÈ­³ªÆ®·ýÀ» Æ÷ÇÔÇÏÁö ¾Ê±â ¶§¹®¿¡ ÈíÀÔµÈ ¾à¹°°ú ¹ÝÀÀÇÏ¿© ÀÏ»êȭź¼Ò¸¦ »ý¼ºÇÏÁö ¾Ê½À´Ï´Ù.

¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå µ¿Çâ :

½ÃÀåÀº ÁÖ·Î ½ÉÀåÁúȯ, ½Å°æÁúȯ, È£Èí±âÁúȯ, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², ¿Ü°úÀû °³ÀÔÀÌ ÃÖÁ¾ÀûÀ¸·Î ÇÊ¿äÇÑ Áúº´¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ¼öÇàµÇ´Â ¼ö¼úÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸¶Ãë ÀÏȸ¿ë¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î Á¦Ç° äÅÿ¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ¸¶ÃëÁ¦ ¹× ±â±¸ »ç¿ë¿¡ ´ëÇÑ Á¤ºÎÀÇ °¡À̵å¶óÀΰú ¾ÈÀü °ü·Ã ÆÄ¶ó¹ÌÅͰ¡ ¾ö°ÝÇØÁö¸é¼­ Á¦Ç° ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ÷´Ü CO2 Èí¼ö Á¦Á¦ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ÇコÄɾî ÁöÃâ È®´ëµµ ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå ¼ºÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ Á¦Ç°º° ºÐ·ù´Â?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ À¯Çüº° ºÐ·ù´Â?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¸¶Ãë¿ë CO2 Èí¼öÁ¦ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Soda Lime
  • Medisorb
  • Dragersorb
  • Amsorb
  • Litholyme
  • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : À¯Çüº°

  • ÇÁ¸®¹Ì¾ö À¯Çü
  • ±âÁ¸ À¯Çü

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Armstrong Medical Ltd.(Eakin Healthcare Group Ltd)
    • Atrasorb
    • Dragerwerk AG & Co. KGaA
    • General Electric Company
    • Intersurgical Ltd.
    • Lowenstein Medical SE & Co. KG
    • Micropore Inc.
    • Molecular Products Group plc(Filtration Group Corporation)
    • Smiths Medical Inc.(ICU Medical Inc.)
LSH

The global anesthesia CO2 absorbent market size reached USD 82.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 132.8 Million by 2033, exhibiting a growth rate (CAGR) of 5.38% during 2025-2033. The increasing number of surgeries across hospitals and clinics is raising the demand for reliable absorbents, which is stimulating the market.

Anesthesia CO2 absorbent is a specific segment within the anesthesia disposables, which is primarily used to absorb exhaled gases during anesthesia administration. Consisting of strong potassium hydroxide and sodium hydroxide bases that help obtain labile protons from anesthetic molecules to carbon monoxide (CO), these absorbent formulations are instrumental in minimizing anesthetic wastes. The CO2 absorber devices consisting of anesthesia absorbents are incorporated into the ventilatory apparatus of the anesthesia machine between the inspiratory and expiratory limbs of a circle circuit. They function by limiting the flow of fresh gas to closed-circuit conditions and allowing exhaled anesthetic agents to be rebreathed. However, the production of carbon monoxide (CO) can cause health hazards to patients. Certain CO2 absorbents do not contain potassium hydroxide, and sodium hydroxide and consequently do not produce carbon monoxide by reacting with inhaled agents.

Anesthesia CO2 Absorbent Market Trends:

The market is primarily driven by the rising incidences of chronic conditions, such as cardiac disorders, neurological conditions, respiratory diseases, and diabetes. Along with this, the growing geriatric population that is susceptible to developing medical conditions ultimately requiring surgical intervention is providing a significant boost to the market. Besides this, with the rising number of surgeries conducted across numerous healthcare settings, there has been a considerable rise in the demand for anesthesia disposables, thereby contributing to the product adoption across the globe. Various stringent government guidelines and safety parameters regarding the usage of anesthetic drugs and equipment across the healthcare sector are further propelling the product demand. In addition to this, the increasing investments in the research and development (R&D) activities for developing advanced CO2 absorbing formulations and the expanding healthcare expenditure are also providing an impetus to the market growth.

Key Market Segmentation:

Breakup by Product:

  • Soda Lime
  • Medisorb
  • Dragersorb
  • Amsorb
  • Litholyme
  • Others

Breakup by Type:

  • Premium
  • Traditional

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Armstrong Medical Ltd. (Eakin Healthcare Group Ltd), Atrasorb, Dragerwerk AG & Co. KGaA, General Electric Company, Intersurgical Ltd., Lowenstein Medical SE & Co. KG, Micropore Inc., Molecular Products Group plc (Filtration Group Corporation) and Smiths Medical Inc. (ICU Medical Inc.).

Key Questions Answered in This Report

  • 1.How big is the global anesthesia CO2 absorbent market?
  • 2.What is the expected growth rate of the global anesthesia CO2 absorbent market during 2025-2033?
  • 3.What are the key factors driving the global anesthesia CO2 absorbent market?
  • 4.What has been the impact of COVID-19 on the global anesthesia CO2 absorbent market growth?
  • 5.What is the breakup of the global anesthesia CO2 absorbent market based on the product?
  • 6.What is the breakup of the global anesthesia CO2 absorbent market based on the type?
  • 7.What is the breakup of the global anesthesia CO2 absorbent market based on the end user?
  • 8.What are the key regions in the global anesthesia CO2 absorbent market?
  • 9.Who are the key players/companies in the global anesthesia CO2 absorbent market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anesthesia CO2 Absorbent Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Soda Lime
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Medisorb
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Dragersorb
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Amsorb
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Litholyme
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Premium
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Traditional
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Armstrong Medical Ltd. (Eakin Healthcare Group Ltd)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Atrasorb
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Dragerwerk AG & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 General Electric Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Intersurgical Ltd.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 Lowenstein Medical SE & Co. KG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Micropore Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Molecular Products Group plc (Filtration Group Corporation)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Smiths Medical Inc. (ICU Medical Inc.)
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦